Encerrou sessão com sucesso.

Ajude a prevenir e tratar úlceras do pé diabético

Risco de síndrome do pé diabético

A síndrome do pé diabético (SPD) é uma complicação comum do diabetes mellitus que afeta um em cada quatro doentes com diabetes em algum momento de sua vida. [1] O risco de desenvolver SPD aumenta com o tempo.

Bem-vindo, está prestes a entrar numa página exclusiva a profissionais de saúde!

Os conteúdos e produtos que se seguem contêm informação especializada, destinando-se, nos termos da lei, exclusivamente a profissionais de saúde.


Ao confirmar que é um profissional de saúde, antes de entrar na página, reconhece ser detentor das qualificações técnicas e profissionais necessárias ao entendimento dos conteúdos disponibilizados, e da importância de os não divulgar a terceiros, assumindo integral responsabilidade pelo uso das informações a que vai aceder.

Sim, confirmo que sou profissional de saúde Sim, confirmo que sou profissional de saúde. Cancelar Não, não sou profissional de saúde.

Ilustração do pé

Gama de produtos Linovera

ilustração de úlcera do pé diabético de grau 1

Gama de produtos Prontosan
Gama Askina Calgitrol
Penso de espuma Askina DresSil Border

ilustração de úlcera do pé diabético de grau 2

Gama de produtos Prontosan
Gama Askina Calgitrol
Askina Sorb e Askina DresSil

ilustração de úlcera do pé diabético grau 3

Gama de produtos Prontosan
Gama Askina Calgitrol
Penso Askina Foam
Penso Askina Carbosorb

ilustração de úlcera do pé diabético grau 4

Gama de produtos Prontosan
Gama Askina Calgitrol
Penso Askina Foam
Penso Askina Carbosorb
Um homem está ao lado do seu médico, ambos sorriem para a câmara

Prevenção da amputação

Conhece a história do João, o homem cuja amputação do pé foi evitada por um representante de vendas da B. Braun?

Saiba mais sobre como o tratamento de feridas com Prontosan® e Askina® mudou a situação.

Leia a história completa

Prevenção e proteção cutânea

Linovera® Emulsion

Chronic wounds are a major global medical concern,1 significantly impacting patients’ quality of life,2 while also affecting close family and relatives. Chronic wounds also cause considerable financial burden3 on the healthcare system and society.Topical preventive measures such as Linovera® Emulsion are needed to avoid higher healthcare expenditures and preserve patients’ health. They can be used with the goal of promoting integrity of the skin and providing essential moisturizing.4HOFA-containing topical formulations have become an ideal therapeutic option that is part of the clinical protocols for nursing action in the prevention and treatment of ulcers.5Linovera® Emulsion is a light emulsion moisturizing cream composed of:Hyperoxygenated fatty acids (HOFA) originated from sunflower oil naturally rich in linoleic acid,6 an essential fatty acid important in the maintenance of epidermal integrity and the natural skin’s water barrier.7 Some of the HOFA properties can increase skin resistance, reduce dehydration, reduce friction and pressure forces8 and improve microcirculation.9  Vegetable extracts formulated to provide additional benefits such as skin conditioning, humectant and tonic, enhancing the activity of the product.How Linovera® Emulsion can be usedThanks to its content of HOFA and vegetable extracts, Linovera® Emulsion can be useful in the prevention of skin breakdown (e.g. pressure ulcers, vascular ulcers, and diabetic foot ulcers) or in the management of already impaired skin8,10 helping to provide the best care for your patients.With its creamy consistency, Linovera® Emulsion is easy to apply on large body areas, such as limbs and feet11.CompositionHyperoxygenated fatty acids derived from sunflower oil (emollient)Aloe Barbadensis extract (skin conditioning, emollient, humectant)Asian Centella oil extract (skin conditioning, skin tonic, soothing agent)Rosemary essential oil (organoleptic)Ginkgo biloba (skin conditioning)IndicationsLinovera® Emulsion is indicated: For patients whose skin integrity is at riskFor prevention of pressure ulcers, vascular ulcers and diabetic foot ulcersFor treatment of stage 1  pressure ulcersFor large skin surfaces, such as whole lower limbs

Tratamento da infeção da ferida

Askina® Calgitrol® Paste

Askina® Calgitrol® Paste is a sterile primary dressing consisting of an ionic silver alginate matrix in paste form, designed to treat chronic wounds which are infected or at high risk of infection.   The paste form, due to its water content, provides immediate availability of silver ions. Additionally, the ionic exchange with the wound exudate, delivers a sustained release of ionic silver to the wound bed.1   It is supplied sterile in a 15 g tube. The tube has a cannula to aid application of the paste into tunnels, sinuses, and all deep wounds. 2

Askina® Calgitrol® Ag+

Askina® Calgitrol® Ag+ is a wound dressing that combines antimicrobial silver with strengthening cellulose fiber to manage wound infection and high exudate. The dressing promotes healing in a moist environment.  When applied, Askina® Calgitrol® Ag+ responds by forming a gel on contact with wound exudate. The gelling formation traps, locks in and kills the bacteria away from the wound bed. It contains encapsulated nanoparticles of ionic silver encrusted into the strengthening cellulose fiber. The nanoparticles act as a reservoir of ionic silver and are released gradually in contact with wound fluid to kill bacteria and microorganisms within the dressing.Under the supervision of a healthcare professional, Askina® Calgitrol® Ag+ antimicrobial wound dressings may be used for:All agesModerately to heavily exuding woundsChronic wounds, e. g. leg ulcers, pressure ulcers and diabetic ulcersSurgical wounds, e. g. post-operative, wounds left to heal by secondary intent and donor sitesTraumatic wounds, e. g. abrasions and lacerationsPartial thickness burnsIf required, the dressings can be used in conjunction with a suitable moisture-retaining secondary dressing to keep the product in place and/or under compression.

Controlo do exsudado

Askina® DresSil Active

Askina® DresSil Active is a multilayer silicone dressing with border designed to provide active exudate management. Its multilayer structure improves exudate retention and absorption while maintaining the adequate moisture level in the wound1. This may reduce the frequency of dressing changes, thereby saving nursing time and allowing more time to be dedicated to patients and their care2.  Askina® DresSil Active is designed for a wide range of exuding wounds such as:Pressure ulcersLeg and foot ulcersTraumatic wounds (e.g. skin tears)Surgical wounds It can also be used on dry/necrotic wounds in combination with gels. The dressing may also be used as part of a prophylactic therapy to help prevent skin damage, e.g. pressure ulcers.

Askina® Carbosorb

Askina® Carbosorb provides a combination of a superabsorbent wound dressing and activated charcoal. Most wounds have a slight odor, and malodor is the most distressing and socially isolating symptom associated with wounds. With Askina® Carbosorb, you can manage excess exudate and malodor at the same time and have therefore more time to care for your patients.Box of 10.

Askina® Foam

Askina® Foam is a soft, two-layered, non-adherent dressing that is designed to absorb and retain moderate to high wound exudate while providing a moist wound environment to promote healing. The outer vapor-permeable polyurethane film physically protects the wound from water and bacteria.The soft and flexible polyurethane foam provides an excellent conformability to adapt to different wound locations on the body.Askina® Foam wound dressing may be used for: Moderately to heavily exuding woundsChronic wounds, e. g. pressure ulcers, leg and foot ulcersTraumatic wounds, e. g. first and second-degree burns, and surgical wounds

Askina® Sorb Rope

Askina® Sorb Rope is the rope version of Askina® Sorb. It is a sterile primary wound dressing made of fibers containing 85% of calcium alginate and 15% of carboxymethylcellulose (CMC).When in contact with wound exudate, the alginate-CMC fibers are fast gelling, resulting from an ionic exchange between calcium ions from the dressing and sodium ions from theexudate, so as to form a soft moist gel conducive to natural healing. 

Askina® Sorb

Askina® Sorb dressing is a highly absorbent dressing composed of calcium alginate and sodium carboxymethylcellulose (CMC) fibers. The dressing can absorb large amounts of exudate and form a gel which maintains a moist healing environment. Askina® Sorb is available in sheet and rope forms. Askina® Sorb is indicated for moderately to heavily exuding wounds, such as diabetic foot ulcers, pressure ulcers, leg ulcers, superficial and partial thickness burns, donor sites, post-operative wounds and traumatic wounds.

Referências

  1. Rümenapf G, Morbach S, Rother U, Uhl C, Görtz H, Böckler D, Behrendt CA, Hochlenert D, Engels G, Sigl M; Kommission PAVK und Diabetisches Fußsyndrom der DGG e. V.. Diabetisches Fußsyndrom – Teil 1 : Definition, Pathophysiologie, Diagnostik und Klassifikation [Diabetic foot syndrome-Part 1 : Definition, pathophysiology, diagnostics and classification]. Chirurg. 2021 Jan;92(1):81-94. German. doi: 10.1007/s00104-020-01301-9. PMID: 33170315; PMCID: PMC7819949.
  2. Sommer TC, Lee TH. Charcot foot: the diagnostic dilemma. Am Fam Physician. 2001 Nov 1;64(9):1591-8. Erratum in: Am Fam Physician 2002 Jun 15;65(12):2436-8. PMID: 11730314.
  3. Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012 Jun;11(6):521-34. doi: 10.1016/S1474-4422(12)70065-0. Epub 2012 May 16. PMID: 22608666; PMCID: PMC4254767.
  4. Takeo M, Lee W, Ito M. Wound healing and skin regeneration. Cold Spring Harb Perspect Med. 2015 Jan 5;5(1):a023267. doi: 10.1101/cshperspect.a023267. PMID: 25561722; PMCID: PMC4292081.
  5. Lauterbach S, Kostev K, Kohlmann T. Prevalence of diabetic foot syndrome and its risk factors in the UK. J Wound Care. 2010 Aug;19(8):333-7. doi: 10.12968/jowc.2010.19.8.77711. PMID: 20852505
  6. Sämann A, Tajiyeva O, Müller N, Tschauner T, Hoyer H, Wolf G, Müller UA. Prevalence of the diabetic foot syndrome at the primary care level in Germany: a cross-sectional study. Diabet Med. 2008 May;25(5):557-63. doi: 10.1111/j.1464-5491.2008.02435.x. Epub 2008 Mar 14. PMID: 18346154.
  7. Strain WD, Paldánius PM. Diabetes, cardiovascular disease and the microcirculation. Cardiovasc Diabetol. 2018 Apr 18;17(1):57. doi: 10.1186/s12933-018-0703-2. Erratum in: Cardiovasc Diabetol. 2021 Jun 11;20(1):120. PMID: 29669543; PMCID: PMC5905152.
  8. Olm M, Kühnl A, Knipfer E, Salvermoser M, Eckstein HH, Zimmermann A. Operative Versorgung von Diabetikern mit vaskulären Komplikationen : Sekundärdatenanalyse der DRG-Statistik von 2005 bis 2014 in Deutschland [Operative treatment of diabetics with vascular complications : Secondary data analysis of diagnosis-related groups statistics from 2005 to 2014 in Germany]. Chirurg. 2018 Jul;89(7):545-551. German. doi: 10.1007/s00104-018-0628-z. PMID: 29589075
  9. Narres M, Kvitkina T, Claessen H, Droste S, Schuster B, Morbach S, Rümenapf G, Van Acker K, Icks A. Incidence of lower extremity amputations in the diabetic compared with the non-diabetic population: A systematic review. PLoS One. 2017 Aug 28;12(8):e0182081. doi: 10.1371/journal.pone.0182081. PMID: 28846690; PMCID: PMC5573217.
  10. Jeon BJ, Choi HJ, Kang JS, Tak MS, Park ES. Comparison of five systems of classification of diabetic foot ulcers and predictive factors for amputation. Int Wound J. 2017 Jun;14(3):537-545. doi: 10.1111/iwj.12642. Epub 2016 Oct 10. PMID: 27723246; PMCID: PMC7949506.
  11. Santema TB, Lenselink EA, Balm R, Ubbink DT. Comparing the Meggitt-Wagner and the University of Texas wound classification systems for diabetic foot ulcers: inter-observer analyses. Int Wound J. 2016 Dec;13(6):1137-1141. doi: 10.1111/iwj.12429. Epub 2015 Feb 26. PMID: 25720543; PMCID: PMC7949589.
  12. Wagner FW. The dysvascular foot: a system for diagnosis and treatment. Foot Ankle 1981;2